Using a blood test to guide treatment after liver cancer surgery
Part of Cancer clinical trials.
This trial studies whether a blood test can predict if liver cancer comes back after surgery or ablation, and whether an immunotherapy drug (PD-1 inhibitor) can help prevent recurrence. It may help guide treatment to keep the cancer from returning.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have been newly diagnosed with liver cancer (not a recurrence) and have not yet had any cancer treatment.
- You must have had a radical treatment, like surgery to remove the tumor or microwave ablation.
- You must have at least one factor that increases the risk of the cancer coming back, such as tumor larger than 5 cm, multiple tumors, or cancer cells in blood vessels.
- Your liver function must be acceptable (Child-Pugh score 7 or less).
- You must be in generally good health (able to do your daily activities with little or no help).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a tailored treatment plan after surgery for liver cancer that shows a specific blood vessel pattern (VETC). The goal is to find the best follow-up therapy to lower the chance of cancer coming back.
This trial tests whether giving an immunotherapy drug after surgery can help prevent liver cancer from coming back. The drug works by helping your immune system fight any remaining cancer cells.
This study tests a treatment given before surgery for liver cancer that is at high risk of coming back. You would receive a combination of chemotherapy directly into the liver artery (HAIC), a targeted pill (lenvatinib), and an immunotherapy drug (a PD-1 inhibitor) — if a computer model predicts you might benefit.
This trial uses a simple blood test to check for signs of liver cancer coming back after surgery. It may help doctors catch a return earlier and guide further treatment.
This study checks whether a simple blood test (called ctDNA) can predict if liver cancer will come back after surgery. It compares the blood test to a standard lab result from the removed tumor, which may help doctors plan better follow-up care.
This trial uses a computer model to predict if your liver cancer might come back aggressively after surgery. If you are at high risk, you may receive additional treatment before surgery to lower that risk.
Hear when a new Minimal Residual Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.